News for Lyra Therapeutics, Inc. (LYRA)

Key Highlights: Lyra Therapeutics (LYRA) aims to raise $5 million through a strategic stock offering and private placement.Potential additional capital of $9.8

Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placem

Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial. Click here to find out why I rate LYRA stock a Buy.

H.C. Wainwright has amended its price target for Lyra Therapeutics (LYRA), increasing it significantly from $2 to $16. This adjustment follows the company's rec

Shares are higher in Asia after U.S. stock indexes drifted closer to records

U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average inching up 0.08% to 42,305.48, the S&P 500 advancing 0.4% to 5,935.94.

Lyra Therapeutics (LYRA) shares surged 376% following successful Phase 3 trial results. Wall Street analysts offer a cautious one-year price target, ind

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday. The Dow traded down 0.49% to 42,064.07 while the NASD...

Lyra Therapeutics Inc. (LYRA) stock soared nearly 417% to $25.50, peaking at $37.50 intraday, after positive ENLIGHTEN 2 Phase 3 trial results for LYR-210, showing a significant 1.13-point improvement (p=0.0078) in CRS symptoms at week 24. LYR-210’s success in treating chronic rhinosinusitis without nasal polyps positions Lyra to advance its…

U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points on Monday. Following the market opening Monday, the Dow traded down 0.7...

U.S. stock futures were slightly lower on Tuesday after ending largely flat on Monday. Futures of major benchmark indices were trading lower in premarket.

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to

**media[566101]**

Significant Reduction in Holdings On December 31, 2024, Citadel Advisors LLC (Trades, Portfolio) executed a substantial reduction in its holdings of Lyra Therap

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 21.74% and 51.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Cash Position: Cash, cash equivalents, and short-term investments totaled $51.6 million as of September 30, 2024, providing sufficient funding into Q1 2026.Res

-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the...

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings